Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

DI MARCO, Vito
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.710
EU - Europa 5.490
AS - Asia 1.409
SA - Sud America 14
AF - Africa 11
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 8
Totale 23.652
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.677
IT - Italia 1.787
CN - Cina 1.119
FI - Finlandia 1.086
UA - Ucraina 761
IE - Irlanda 415
DE - Germania 377
GB - Regno Unito 332
RU - Federazione Russa 197
SE - Svezia 178
RO - Romania 92
FR - Francia 82
IN - India 70
BE - Belgio 69
TR - Turchia 60
KR - Corea 50
HK - Hong Kong 31
CA - Canada 29
CZ - Repubblica Ceca 25
IR - Iran 25
NL - Olanda 19
CH - Svizzera 15
GR - Grecia 11
PL - Polonia 11
AT - Austria 9
JP - Giappone 9
EU - Europa 8
UZ - Uzbekistan 8
AU - Australia 7
ES - Italia 7
LB - Libano 6
SG - Singapore 6
BG - Bulgaria 5
BR - Brasile 5
EG - Egitto 5
MY - Malesia 4
VE - Venezuela 4
ID - Indonesia 3
MM - Myanmar 3
NG - Nigeria 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CU - Cuba 2
DK - Danimarca 2
EC - Ecuador 2
GH - Ghana 2
MX - Messico 2
NO - Norvegia 2
PT - Portogallo 2
VN - Vietnam 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
CL - Cile 1
CM - Camerun 1
CO - Colombia 1
EE - Estonia 1
IL - Israele 1
IQ - Iraq 1
JO - Giordania 1
LK - Sri Lanka 1
MC - Monaco 1
MD - Moldavia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
RS - Serbia 1
SA - Arabia Saudita 1
Totale 23.652
Salva come PNG Salva come JPEG
Città #
Fairfield 2.836
Ashburn 1.558
Woodbridge 1.436
Chandler 1.319
Houston 1.129
Wilmington 1.129
Seattle 1.083
Cambridge 992
Ann Arbor 867
Palermo 480
Jacksonville 414
Dublin 413
Medford 397
Des Moines 326
Altamura 286
Nanjing 262
Princeton 252
Lawrence 213
San Diego 181
Boardman 144
New York 122
Beijing 110
Tulsa 109
Shenyang 96
Dearborn 82
Jinan 72
Nanchang 70
Brussels 68
Changsha 61
Ludwigshafen am Rhein 61
Milan 61
Hebei 60
Jiaxing 60
Tianjin 56
London 55
Izmir 54
Falls Church 45
Zhengzhou 44
Saint Petersburg 41
Kumar 40
Los Angeles 39
San Paolo di Civitate 39
Seongnam 36
Ningbo 35
Phoenix 33
Redwood City 26
Verona 26
Bremen 24
Ottawa 24
Taizhou 24
Auburn Hills 23
Helsinki 23
Lanzhou 23
San Mateo 23
Venice 22
Brno 21
Hangzhou 20
Guangzhou 19
Orange 19
Rome 19
Kunming 18
Tehran 16
Washington 16
Pune 15
Kilburn 14
Norwalk 14
Düsseldorf 13
Fuzhou 13
Central 12
Chicago 12
Hounslow 11
Redmond 11
Tappahannock 11
Indiana 10
Napoli 10
Central District 9
Hefei 9
Taiyuan 9
Atlanta 8
Haikou 8
Hong Kong 8
Lake Forest 8
Moscow 8
Chiswick 7
Edinburgh 7
Seoul 7
Aragona 6
Den Haag 6
Hanover 6
Mehlingen 6
Munich 6
Mussomeli 6
Padova 6
Aachen 5
Catania 5
Durham 5
Islington 5
San Francisco 5
Vicopisano 5
Brescia 4
Totale 17.962
Salva come PNG Salva come JPEG
Nome #
The presence of white matter lesions is associated with the fibrosis severity of nonalcoholic fatty liver disease 199
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 190
Obstructive Sleep Apnea Is Associated with Liver Damage and Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 189
Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. 188
Therapy with lamivudine and steroids in a patient with acute hepatitis B and rapidly progressive glomerulonephritis. 187
Liver eosinophilic infiltrate is a significant finding in patients with chronic hepatitis C. 182
Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection 180
Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection. 179
PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease 174
HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated- or standard-interferon and ribavirin 173
Survival of Patients with Hepatocellular Carcinoma (HCC) Treated by Percutaneous Radio-Frequency Ablation (RFA) Is Affected by Complete Radiological Response 171
Breaking bad news: How to cope 170
Visceral adiposity index is associated with significant fibrosis in patients with non-alcoholic fatty liver disease 168
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 165
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 165
Targeted Therapies in Hepatocellular Carcinoma 160
Assessment of hepatitis C virus-RNA clearance under combination therapy for hepatitis C virus genotype 1: performance of transcription-mediated amplification assay 155
High liver RBP4 protein content is associated with histological features in patients with genotype 1 chronic hepatitis C and with nonalcoholic steatohepatitis 154
The severity of steatosis influences liver stiffness measurement in patients with nonalcoholic fatty liver disease 150
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 149
Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C 149
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 149
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 147
Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation 146
Prophylaxis and treatment of hepatitis B in immunocompromised patients. 145
Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b 145
Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. 144
751 RETINOL-BINDING PROTEIN 4 (RBP4): A NEW MARKER OF G1 HCV-INDUCED STEATOSIS 143
Phylogenetic Analysis of isolates from new cases of HBV infection in Southern Italy. 142
TM6SF2 rs58542926 is not associated with steatosis and fibrosis in largecohort of patients with genotype 1 chronic hepatitis C 142
Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 141
STAGING OF FIBROSIS BY LIVER STIFFNESS MEASUREMENT IN THALASSEMICS WITH IRON OVERLOAD 140
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 139
Adefovir for lamivudine resistant HBV: More than meets the eye. 139
Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. 139
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 138
Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine 137
Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems 137
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 137
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 136
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 136
Body Mass Index and Liver Stiffness Affect Accuracy of Ultrasonography in Detecting Steatosis in Patients With Chronic Hepatitis C Virus Genotype 1 Infection 136
Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis C virus genotype 1. 134
NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients 134
The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. 133
Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. 133
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 133
Histomorphology of healthy oral mucosa in untreated celiac patients: unexpected association with spongiosis. 133
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 133
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study 130
Chronic hepatitis B: who to treat and which choice of treatment? 130
Cost-Effectiveness of Boceprevir or Telaprevir for Untreated Patients with Genotype 1 Chronic Hepatitis C 130
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 130
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 129
Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. 129
The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. 129
A patient with acute hepatitis C and possible IFN toxicity [2] 129
Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients with Non-alcoholic Fatty Liver Disease 129
Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients 127
Hyperferritinemia is a risk factor for steatosis in chronic liver disease. 127
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 127
Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection. 126
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 126
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 126
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients 126
Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial 125
Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials 125
Halitosis: could it be more than mere bad breath? 125
SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C 125
The presence of White Matter Lesions is not associated with Non-alcoholic Fatty Liver Disease but with its histological severity 125
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 125
Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. 125
Retinol-binding protein 4 (RBP4) : a new marker of G1 HCV-induced steatosis 124
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. 121
Liver disease in chelated transfusion-dependent thalassemics: the role of iron and chronic hepatitis C 121
High sCD36 plasma level is associated with steatosis and its severity in patients with genotype 1 chronic hepatitis C 121
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 121
HCV clearance among hemophiliacs and beta-thalassemics 120
Sorafenib: from literature to clinical practice 120
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 120
PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C 120
Hepatic expression of cyclooxygenase-2 in non alcoholic fatty liver disease 119
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C 119
Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD 119
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 118
Impact of HBV genotypes A and D genetic variability on infection evolution 118
Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values 118
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. 117
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study 115
Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. 115
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy 115
Fibronectin type III domain-containing protein 5 rs3480 A>G polymorphism, irisin, and liver fibrosis in patients with Nonalcoholic fatty liver disease 115
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 115
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study 114
Association of vitamin D serum levels and its common genetic determinants with severity of liver fibrosis in genotype 1 chronic hepatitis C patients 114
Insulin resistance is associated with steatosis in non-diabetic patients with genotype 1 chronic hepatitis C 114
Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model 113
TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1. 112
Methylenetetrahydrofolate reductase homozygosis and low-density lipoproteins in patients with genotype 1 chronic hepatitis C 112
Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. 111
Totale 13.694
Salva come PNG Salva come JPEG
Categoria #
all - tutte 90.196
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 90.196
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.396 0 0 0 0 0 0 0 0 0 0 745 651
2019/20206.918 730 284 421 789 738 851 751 505 743 353 546 207
2020/20213.672 216 319 207 356 297 155 206 260 476 478 339 363
2021/20223.089 137 661 128 95 107 134 172 165 380 372 226 512
2022/20233.964 391 840 51 422 415 628 274 267 429 17 155 75
2023/20241.362 76 246 106 116 133 391 146 86 22 38 2 0
Totale 24.760